AOD-9604
Other ·Insufficient evidence ·Reviewed May 2026
Synthetic fragment of human growth hormone marketed for fat-loss claims. FDA flags limited safety information, immunogenicity/impurity concerns, and serious adverse event signals with unclear causality.
- Unknown product purity, potency, and sterility risk outside regulated drug supply
- Injection-site reactions or infection risk with injectable products
- Immune reactions are possible with peptide impurities or aggregation
- Pregnancy or nursing
- History of cancer or active malignancy unless specifically cleared by an oncologist
The bottom line
Evidence rating insufficient. Most-documented uses: no approved wellness use, human efficacy evidence is insufficient for consumer guidance, reference-only safety profile. 3 sources indexed (2004–2026), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Derived from the lipolytic region of human growth hormone and investigated for lipid metabolism, but human clinical efficacy and long-term safety are not established for consumer use.
Dosing & protocol.
Route-specific guidance is intentionally not provided for unapproved research peptides.
Full safety detail.
Side effects
- Unknown product purity, potency, and sterility risk outside regulated drug supply
- Injection-site reactions or infection risk with injectable products
- Immune reactions are possible with peptide impurities or aggregation
Contraindications
- Pregnancy or nursing
- History of cancer or active malignancy unless specifically cleared by an oncologist
- Use by competitive athletes subject to anti-doping rules
- Use without clinician supervision
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Reviews & position papers
1- 1AOD-9604 MetabolicSource linkedPMIDWilding J · Curr Opin Investig Drugs · 2004
Investigational-drug review; not evidence of approved consumer efficacy.
Mechanistic & preclinical
1- 2Detection and in vitro metabolism of AOD9604Source linkedPMIDCox HD et al. · Drug Test Anal · 2015
Analytical detection/metabolism study; does not establish clinical safety or efficacy.
Reference material
1- 3Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksSource linkedURLU.S. Food and Drug Administration · FDA · 2026
FDA flags significant immunogenicity risk, peptide impurity/API characterization concerns, limited safety information, and serious adverse event signals with unclear causality.
Deep dives & adjacent profiles.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
AOD-9604 in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.